Chainfir Capital says AI drug deal headlines mask reliance on uncertain milestone payments

• Chainfir Capital's AI drug-discovery analysis prioritizes cash received over headline deal values, with most payments contingent on development and commercialization milestones.
• Insilico's Servier collaboration totals up to $888 million, including $32 million in upfront and near-term R&D payments.
• First-half 2026 revenue at Insilico reached approximately $106 million, up 287%; adjusted net profit exceeded $51 million, its first profitable half-year since listing.
• China's AI drug-discovery sector raised RMB 15.77 billion across 57 financings in January-September 2026, exceeding the combined 2023-2025 total.
• The four largest transactions captured roughly 60% of funding, highlighting capital concentration among platforms converting AI capabilities into partner payments.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Chainfir Capital published the original content used to generate this news brief on October 21, 2026, and is solely responsible for the information contained therein.